Skip to main content
. 2017 May 17;38(1):58–74. doi: 10.1177/0271678X17705973

Figure 1.

Figure 1.

Chronic rapamycin treatment reduces mTOR activity in aortas and brain vasculature of LDLR−/− mice. (a) Blood levels of rapamycin in mice of Cohort 1 after 30 weeks of treatment. Blood levels of control-treated animals were below the detection limit (D.L.) of 0.5 ng/ml. (b) Significantly reduced phosphorylation of rpS6, a downstream target of mTOR, in aortas from rapamycin-treated animals (**, p = 0.004, Student’s unpaired t test); (c) Significantly reduced rpS6 phosphorylation in brain vasculature purified from rapamycin-treated animals of Cohort 4 following 20 weeks of treatment (***, F(3,12) = 12.06, p < 0.001, Tukey’s test on a significant effect of treatment, one-way ANOVA); (d) Rapamycin levels in liver in animals of Cohort 4. n = 8–10/group. Data are means ± SEM.